Abstract:OBJECTIVE:To study the effects of pioglitazone on atherosclerosis on ApoE-/- mice, and to investigate the roles of adiponectin and its receptors.METHODS:ApoE-/- mice were fed with high-fat chow for the induction of atherosclerosis and were divided into three subgroups: placebo(n=10), low-dose[10 mg/( kg.d), n=10] pioglitazone therapy, and high-dose[20 mg/( kg.d), n=10] pioglitazone therapy. C57BL/6J wild type mice (n=9) were used as control. Aortic atherosclerosis and intimajmedia thickness (intima-media thickness , IMT) of abdominal aorta were monitored, and plasma adiponectin was also measured. Expression levels of the adiponectin receptor 1(AdipoR1)and adiponectin receptor 2 (AdipoR2) in vessels were analyzed(RT-PCR).RESULTS:(1) Aortic atherosclerotic lesions were observed in ApoE-/- mice but not in wild type mice. Interestingly, these lesions were significantly prevented by high-dose pioglitazone therapy. Compared with wild type mice, ApoE-/- mice had increased IMT of abdominal aorta [(0.290+/-0.063 vs 0.178+/-0.012) cm, P<0.01] that was significantly reversed by high-dose pioglitazone therapy [(0.208+/-0.012 vs 0.290+/-0.063) cm, P<0.05]. (2) The level of plasma adiponectin was significantly lower in ApoE-/- mice [(12.41+/-3.84 vs 18.96+/-4.89) microg/L, P<0.05), which could be increased by low-and high-dose pioglitazone therapy (18.78+/-7.24 microg/L vs 12.41+/-3.84 microg/L, P<0.05; and 24.00+/-4.71 microg/L vs 12.41+/-3.84 microg/L, P<0.05). (3) Compared with wild type mice, ApoE-/- mice had reduced AdipoR1 mRNA level(0.789+/-0.167 vs 0.950+/-0.071, P<0.05) and reduced the ratio of AdipoR1/AdipoR2 (0.940+/-0.102 vs 1.039+/-0.062, P<0.05); high dose pioglitazone therapy could upregulate AdipoR1, AdipoR2 mRNA expression and increase the ratio of AdipoR1/AdipoR2 (1.063+/-0.051 vs 0.940+/-0.102,P<0.01).CONCLUSION:Pioglitazone inhibits aortic atherosclerosis in ApoE-/- mice, and these effects are correlated with increased plasma adiponectin level and the expression of AdipoR1 mRNA in vessels.

Pioglitazone Attenuates Aging-Related Disorders in Aged Apolipoprotein E Deficient Mice.

Pioglitazone Attenuates Atherosclerosis in Diabetic Mice by Inhibition of Receptor for Advanced Glycation End-Product (RAGE) Signaling.

Rosiglitazone Via Upregulation of Akt/Enos Pathways Attenuates Dysfunction of Endothelial Progenitor Cells, Induced by Advanced Glycation End Products

The PPARgamma agonist pioglitazone ameliorates aging-related progressive renal injury

Anti-atherosclerotic Effects and Possible Mechanism of Pioglitazone on Apolipoprotein E Knockout Mice

[Pioglitazone Ameliorates Atherosclerosis in Apoe Knockout Mice Through Transforming Growth Factor-Β/smad Signaling and Adaptive T Cell Immunity].

Pioglitazone alleviates the mitochondrial apoptotic pathway and mito-oxidative damage in the d-galactose-induced mouse model

Pioglitazone Hydrochloride Extends the Lifespan of Caenorhabditis elegans by Activating DAF-16/FOXO- and SKN-1/NRF2-Related Signaling Pathways

[Role of Adiponectin and Its Receptors in Anti-Atherosclerotic Effects of Pioglitazone on ApoE Knocked out Mice].

PPARγ agonists delay age‐associated metabolic disease and extend longevity

Inhibition Of Reactive Oxygen Species/Extracellular Signal-Regulated Kinases Pathway By Pioglitazone Attenuates Advanced Glycation End Products-Induced Proliferation Of Vascular Smooth Muscle Cells In Rats

Pioglitazone Ameliorates Atherosclerotic Lesions With The Modification Of The Balance Of Effector And Regulatory T Cells In Apolipoprotein E Deficient Mice

Pioglitazone Alleviates Inflammation in Diabetic Mice Fed a High‐fat Diet Via Inhibiting Advanced Glycation End‐product‐induced Classical Macrophage Activation

Pioglitazone Attenuates Advanced Glycation End Products-Induced Apoptosis and Calcification by Modulating Autophagy in Tendon-Derived Stem Cells

Abstract 4887: The Thiazolidinedione Pioglitazone up-regulates Vascular Telomere Regulating Proteins and Prevents Cellular Senescence in Mice

Pioglitazone Reduces Β Amyloid Levels Via Inhibition of PPARγ Phosphorylation in a Neuronal Model of Alzheimer’s Disease

Pioglitazone Inhibits Advanced Glycation End Product-Induced Matrix Metalloproteinases and Apoptosis by Suppressing the Activation of MAPK and NF-κB.

Effects of Pioglitazone on Treg Cells and Atherosclerosis in Uremic Apoe-/- Mice

Pioglitazone Ameliorates Memory Deficits In Streptozotocin-Induced Diabetic Mice By Reducing Brain Beta-Amyloid Through Ppar Gamma Activation

PPAR-<i></i> Activation Alleviates Osteoarthritis through Both the Nrf2/NLRP3 and PGC-1<i></i>/<i></i><sub>m</sub> Pathways by Inhibiting Pyroptosis

GW29-e0161 Effect of Pioglitazone on the Development of Atherosclerosis and Its Underlying Mechanisms in Diabetic Apolipoprotein E-Null Mice